AI detects Alzheimer's disease SIX years early - with 100% accuracy in small study

A new AI system is 100% accurate in its predictions of Alzheimer's made based on subtle metabolic brain changes - and it catches the the disease six years early, a University of San Francisco study shows.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

The blood-brain barrier surrounds blood vessels in the brain, enforcing restrictions on the passage of molecules and cells between brain and blood supply. Like all bodily systems, the blood-brain barrier breaks down with aging, yet another consequence of rising levels of cellular damage and disarray. The passage of inappropriate cells and molecules into the brain is thought to cause a range of issues, but, as is the case for all aspects of the biochemistry of the brain, this is a very complex environment and set of processes. Firm answers are ever elusive, and a great deal of the fine detail of the aging of the brain has y...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
This findings of this study support an association between functional performance and Alzheimer disease neuroimaging biomarkers very early in the dementia pathophysiology.Journal of the American Geriatrics Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Authors: Louie R PMID: 30642438 [PubMed - in process]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Authors: McCleery J, Flicker L, Richard E, Quinn TJ PMID: 30642437 [PubMed - in process]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Authors: Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dichgans M, Iadecola C, Love S, Bath PM, Markus HS, Salman RA, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, González HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O'Brien JT, Skoog I, Pantoni L, Gustafson DR, Biessels GJ, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". Alzheimers Dement. 2019 Jan;15(1):153-157 Authors: Jagust W, Jack CR, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R PMID: 30642435 [PubMed - in process]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
ConclusionsThese outcomes provide valuable evidences for therapeutic mechanism investigation of Danshen in AD treatment, and such an approach could be transferred to unravel the mechanism of other traditional Chinese medicine (TCM) and diseases.
Source: Metabolomics - Category: Biology Source Type: research
AbstractAlzheimer ’s disease (AD) is the most prevalent neurodegenerative disorder in the world, and intracellular neurofibrillary tangles and extracellular amyloid-beta protein deposits represent the major pathological hallmarks of the disease. Currently available treatments provide some symptomatic relief but fai l to modify primary pathological processes that underlie the disease. Erythropoietin (EPO), a hematopoietic growth factor, acts primarily to stimulate erythroid cell production, and is clinically used to treat anemia. EPO has evolved as a therapeutic agent for neurodegeneration and has improved neur ologic...
Source: NeuroMolecular Medicine - Category: Neurology Source Type: research
AbstractRetinoid X receptor (RXR) ligands have a wide range of beneficial effects in mouse models of Alzheimer ’s disease (AD). Recently accumulated evidence suggests that early neuroinflammation may be a therapeutic target for AD treatment. We therefore investigated the anti-inflammatory effects of the prenylated flavanoids SPF1 and SPF2, which were previously isolated from root ofSophora tonkinensis and identified as potent ligands for RXR, and potential mechanisms involved. SPF1 and SPF2 efficiently reduced interleukin (IL)-1 β messenger RNA (mRNA) and IL-6 mRNA levels in lipopolysaccharide-stimulated and tum...
Source: Journal of Natural Medicines - Category: Drugs & Pharmacology Source Type: research
Soluble Amyloid Precursor Protein α: Friend or Foe? Adv Exp Med Biol. 2018;1112:177-183 Authors: Corbett NJ, Hooper NM Abstract The "amyloidogenic" proteolytic processing of the cell surface amyloid precursor protein (APP) produces amyloid-β, which causes a range of detrimental effects in the neuron, such as synaptic loss, and plays a key role in Alzheimer's disease. In contrast, "non-amyloidogenic" proteolytic processing, which involves the cleavage of APP by α-secretase, produces soluble amyloid precursor protein α (sAPPα) and is the most predominant p...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Alzheimer's | Brain | Health | Neurology | Study